Target Name: MIR3192
NCBI ID: G100422875
Review Report on MIR3192 Target / Biomarker Content of Review Report on MIR3192 Target / Biomarker
MIR3192
Other Name(s): hsa-miR-3192-5p | microRNA 3192 | hsa-mir-3192 | hsa-miR-3192-3p | mir-3192 | MicroRNA 3192

MIR3192: A Potential Drug Target and Biomarker

MIR3192, a drug candidate for the treatment of various diseases, has been shown to have a unique mechanism of action and potential for targeting the liver cancer. The molecule has been shown to induce apoptosis (programmed cell death) in cancer cells, leading to a decrease in the population of cancer cells. This has been shown to have a positive impact on overall patient outcomes.

MIR3192 is a small molecule inhibitor of the B-cell maturation antigen (BCMA), which is a protein that is expressed in the majority of human cancer cells. BCMA is a glycoprotein that is involved in the regulation of cancer cell growth and survival. By inhibiting BCMA, MIR3192 has been shown to reduce the growth and survival of cancer cells.

In addition to its potential as a cancer treatment, MIR3192 has also been shown to have potential as a biomarker. The molecule has been shown to be able to cross the blood-brain barrier and to induce apoptosis in brain cancer cells. This suggests that it may be able to be used as a diagnostic tool for brain cancer.

MIR3192 has also been shown to have potential as a target for other diseases. The molecule has been shown to inhibit the activity of the protein PDGF-BB, which is involved in the development and maintenance of cancer cells. This suggests that MIR3192 may be able to be used as a treatment for diseases that are caused by the over-expression of PDGF-BB.

In conclusion, MIR3192 has shown promising potential as a drug target and biomarker. Further research is needed to fully understand its mechanism of action and to determine its potential effectiveness in treating various diseases.

Protein Name: MicroRNA 3192

The "MIR3192 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3192 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679